(BIOLIN, NR/BB/BB)
"*TRUMP: 100% TARIFF ON BRANDED, PATENTED PHARMACEUTICAL PRODUCT" - BBG
"*TRUMP: PHARMA TARIFFS EFFECTIVE OCT. 1" - BBG
US plant construction key to avoid tariffs, negative for Biocon.
The US is reported to be Biocon's largest market, with the bulk of drug manufacturing in Bengaluru (India) and Johor (Malaysia). The company has an existing US manufacturing facility in Cranbury, New Jersey, operated by its wholly owned subsidiary Biocon Generics, which focuses on cardiovascular drugs. No new plants under construction. Negative for spreads.

Find more articles and bullets on these widgets:
TYU5 is trading 112-04+, down 0-02 from its close.
The Sep JGB future finish up at 137.33, -.03 versus settlement levels post yesterday's Tokyo close. The intra-session low from yesterday was at 137.22, which was sub late July lows. Focus remains on downside risks to futures, with the 10yr JGB yield biased higher amid fiscal concerns/lack of bond demand. In terms of technicals, a test lower would signal scope for an extension towards 136.57, a Fibonacci projection.
Gold rose on news that President Trump was removing Fed Governor Cook and then added to these gains during the US session. It was up 0.8% to $3393.57/oz, close to the intraday peak, and 3.2% higher this month. It has started today around $3392.2. It was supported by a lower US dollar (BBDXY-0.2%) and lower Treasury yields. If the Fed is skewed with dovish members, then more easing is likely which is positive for non-interest bearing bullion.